Company Profile for ExonHit Therapeutics.Business Editors/Health/Medical Writers --(BUSINESS WIRE) ExonHit Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. is a privately-held company whose mission is to develop novel therapeutics and diagnostics for neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. and cancer. The company is a leader in alternative RNA splicing RNA splicing n. See splicing. RNA splicing, n the process by which base pairs that interrupt the continuity of genetic information in deoxyribonucleic acid are removed from the precursors of messenger holding a premier scientific and intellectual property position in the field. ExonHit's proprietary gene profiling technology, DATAS(TM) (Differential Analysis of Transcripts with Alternative Splicing Alternative splicing is the RNA splicing variation mechanism in which the exons of the primary gene transcript, the pre-mRNA, are separated and reconnected so as to produce alternative ribonucleotide arrangements. ), systematically identifies RNA splicing alterations on a genome-wide scan. RNA splicing is altered during the onset and progression of disease, therefore, by distinguishing discrete splicing splicing /splic·ing/ (spli´sing) 1. the attachment of individual DNA molecules to each other, as in the production of chimeric genes. 2. RNA s. events the company is able to identify landmarks of disease. DATAS(TM) is central to internal drug discovery programs. The company has two drugs currently in clinical trials. In addition, the profiling technology is utilized in broader applications by several external therapeutic and diagnostic collaborators, and to capitalize on Cap´i`tal`ize on` v. t. 1. To turn (an opportunity) to one's advantage; to take advantage of (a situation); to profit from; as, to capitalize on an opponent's mistakes s>. the growing needs for pharmacogenomic tools, and toxicity toxicity /tox·ic·i·ty/ (tok-sis´i-te) the quality of being poisonous, especially the degree of virulence of a toxic microbe or of a poison. prediction assays. ExonHit Therapeutics, founded in 1997, is headquartered in Paris, France and has a US facility in Gaithersburg, Maryland. The company has 68 employees worldwide and has raised a total of 47 million EURO.
Company: ExonHit Therapeutics
Headquarters Address: 217 Perry Parkway
Gaithersburg, Maryland 20877
Main Telephone: 240-683-7070
Website: www.exonhit.com
Type of Organization: Private
Industry: Health: Biotechnology
Key Executives: CEO: Bruno Tocque
CFO: Philippe Rousseau
Vice President: Laurent Bracco
Public Relations
Contact: Sheila Khatri
Phone: 240-683-7050
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion